Trial Outcomes & Findings for Can We Miss Pigmented Lesions in Psoriasis Patients? (NCT NCT01053819)

NCT ID: NCT01053819

Last Updated: 2018-02-23

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

6 participants

Primary outcome timeframe

Patients will complete study within 6 months.

Results posted on

2018-02-23

Participant Flow

Participant milestones

Participant milestones
Measure
Etanercept
Patients will receive six months of treatment with Enbrel 50mg SC given twice a week for the first three months and 50 mg once a week thereafter.
Overall Study
STARTED
6
Overall Study
COMPLETED
6
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Can We Miss Pigmented Lesions in Psoriasis Patients?

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Etanercept
n=6 Participants
open label treatment per FDA approval for 24 weeks
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
6 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
Sex: Female, Male
Male
2 Participants
n=5 Participants
Region of Enrollment
United States
6 participants
n=5 Participants

PRIMARY outcome

Timeframe: Patients will complete study within 6 months.

Population: The data for this Outcome was not collected and due to the length of time, the records have been destroyed.

Outcome measures

Outcome measures
Measure
Etanercept
n=6 Participants
open label treatment per FDA approval for 24 weeks
The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.
0 participants

SECONDARY outcome

Timeframe: Patients will complete the study within 6 months

Population: The data for this Outcome was not collected and due to the length of time, the records have been destroyed.

The data for this Outcome was not collected and due to the length of time, the records have been destroyed.

Outcome measures

Outcome data not reported

Adverse Events

Etanercept

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Boni Elewski, MD

University of Alabama at Birmingham

Phone: 205-502-9960

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place